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To compare the mode of action of rus ~21 with those of protein kinases A and C in the regulation of gene expression in NIH/3T3 cells, we investigat- 
ed the transcriptional activity of various enhancer/promoters and enhancer motifs in the cells transfected with the c-Ha-rusvdi2 complementary 
DNA (cDNA). The results indicate that the c-Ha-rasvau2 protein stimulates the enhancer/promoters of the c&s gene, the metallothionein HA gene, 
the simian virus 40 (SV40) virus genome and the Rous sarcoma (RS) virus genome, and the serum-response element and the 12.O-tetradecanoyl- 
phorbol-13-acetate (TPA)-response lement in a manner independent of protein kinases A and C in NIH/3T3 cells. 
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1. INTRODUCTION 
The ras p21 and its activated form are involved in the 
proliferation of various types of cells (for a review, see 
[l]). It has been reported that TQS p21 may regulate the 
phospholipase C-mediated hydrolysis of phosphoinos- 
itides and consequently modulate protein kinase C 
activity in mammalian cells such as NIH/3T3 cells 
[2,3], but the direct linkage between the phospholipase 
C and ras p21 has not yet been obtained. 
On the other hand, the activated ~0.s p21 stimulates 
the enhancer/promoters of the c-fos gene and the 
polyoma virus genome [4-61. The enhancer/promoters 
of the c-fos gene and the polyoma virus genome contain 
the SRE’, the CRE and/or the TRE, and the transcrip- 
tional activities of these enhancer/promoters are 
regulated by these elements [7-IO]. The SRE and the 
TRE are activated by TPA though protein kinase C in 
various types of cells including NIH/3T3 cells [8-121. 
In the present studies, we have examined the relation- 
ship between the action of the activated ras p21 and 
those of protein kinases A and C in the stimulation of 
various enhancer/promoters and enhancer motifs in 
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NIH/3T3 cells. This paper shows that the activated ras 
p21 stimulates the enhancer/promoters of the c-fos 
gene, the metallothionein IIA gene, the SV40 virus 
genome and the RS virus genome, and the SRE and the 
TRE in a manner independent of protein kinases A and 
C in NIH/3T3 cells. 
2. MATERIALS AND METHODS 
2.1. Materials and chemicub 
NIH/3T3 cells were donated by M. Wigler (Cold Spring Harbor 
Laboratory, Cold Spring Harbor, NY). The pcDSRo expression 
plasmid, pSVZCAT, pRSVCAT, c-fos-luciferase and pRSV- 
luciferase were donated from K. Arai (DNAK Research Institute, 
Palo Alto, CA) [13-16). c-fosCAT (FC4) was a gift from I.M. Verma 
(Salk Institute, San Diego, CA) [17]. pMTCAT (phMTCAT-4) was 
from K. Nose (Tokyo University, Tokyo, Japan) 118). Somatostatin- 
CAT @RI-CAT) was from R.H. Goodman (Tufts-New England 
Medical Center, Boston, MA) [19]. pTKGH was purchased from 
Nicols Institute [20]. 
2.2. Construction of plarmids 
pcDSRoras and pcDSRorusv~‘2 were constructed for expression of 
normal (Gly-12) and activated (Val-12) human c-Ha-rus ~21, respec- 
tively, as described [6]. c-fosCAT and c-fos-luciferase contain the 
O.Ckilobase 5’-flanking sequence of the c-fos gene upstream from 
the CAT and luciferase genes, respectively [16,17]. pSV2CAT con- 
tains the O.dkilobase enhancer/promoter region of the SV40 virus 
genome upstream from the CAT gene [14]. pRSVCAT and pRSV- 
luciferase contain the 0.5-kilobase nhancer/promoter region of the 
RS virus genome upstream from the CAT and luciferase genes, 
respectively [l&16]. pMTCAT and somatostatin-CAT have the 
0.4-kilobase 5 ‘-flanking sequence of the human metallothionein 11~ 
and the 4-kilobase 5’-flanking sequence of the somatostatin genes, 
respectively, upstream from the CAT genes [18,19]. AIL3CAT was 
constructed as described [21]. SRECAT, CRECAT and TRECAT 
were constructed as described [12]. 
2.3. Assays for CAT, growth hormone and luciferuse 
NIH/3T3 cells were transfected with 20,4g of plasmid DNA, con- 
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Fig. 1. Activation of c-fosCAT by cotransfection of the c-Ha-rusVa”* 
cDNA to NIH/3T3 cells. (A) Construction of expression plasmids 
harboring the c-Ha-rar cDNAs. The c-Ha-rus and c-Ha-r&“‘* 
cDNAs were cloned into the pcDSILY expression plasmid to yield 
pcDSRarus and pcDSRcurus”~‘* as described [6]. (B) c-fos CAT 
expression. pcDSRarus or pcDSRcuras’P’* was cotransfected with c- 
fosCAT and pTKGH to NIH/3T3 cells. After 48 h incubation, CAT 
activity and the levels of growth hormone were assayed as described 
under section 2. Lane 1, control; lane 2, pcDSRcrrus; lane 3, 
pcDSRcYrusvs”*. CM and AcCM represent chloramphenicol and its 
acetylated forms, respectively. 
taining 5 pg of pcDSRcuras*“*, 5 fig of pTKGH, 5,4g of the CAT 
construct or 5 pg of the luciferase construct, and pUC18 as a carrier 
as indicated. The levels of the human growth hormone were 
measured as described [12]. CAT and luciferase activities were 
measured as described (14,161. 
3. RESULTS 
3.1. Expression of the CA T and luciferase fusion genes 
by cotransfection of the c-Ha-rasw’12 cDNA 
The c-Ha-ras and c-Ha-rasv8”2 cDNAs were cloned 
into the pcDSRa expression plasmid under the control 
of the SRa promoter (pcDSRcuras and pcDStirasva”‘) 
(Fig. 1A) [6]. pcDSRwasva”2 showed transforming ac- 
tivity after transfection to NIH/3T3 cells (data not 
shown). Various CAT fusion genes (c-fosCAT, 
pMTCAT, pSV2CAT, pRSVCAT and somatostatin- 
CAT) were tested for their responses to the ras con- 
structs. To measure the relative efficiency of transfec- 
tion and to normalize the separate experiments, the 
human growth hormone gene under the transcriptional 
control of the promoter of the thymidine kinase gene 
(pTKGH) was cotransfected with the CAT fusion genes 
to NIH/3T3 cells. Cotransfection of pcDStirasV8”2 or 
addition of TPA directed expression of c-fosCAT, 
pMTCAT, pSV2CAT and pRSVCAT but not 
somatostatin-CAT (Fig. 1B and Table I). Addition of 
Bt2cAMP directed expression of c-fosCAT, pSVZCAT, 
pRSVCAT and somatostatin-CAT but not pMTCAT. 
Cotransfection of pcDSRcvras conferred a minimal in- 
crement of CAT activity derived from these CAT fu- 
sion genes. Cotransfection of the control plasmid 
(pcDSI&) alone showed no effect on CAT expression. 
CAT activity derived from the CAT construct lacking 
the enhancer/promoter sequence was negligible in the 
cells cotransfected with the ras constructs or supplied 
with TPA or BtzcAMP (data not shown). 
To examine the reporter gene other than the CAT 
gene, the enhancer/promoter of the c-fos gene or the 
RS virus genome ligated to the luciferase gene (c-fos- 
luciferase or pRSV-luciferase) was employed as another 
reporter of transcriptional activity of the 
enhancer/promoter of the c-fos gene or the RS virus 
genome. c-fos-luciferase or pRSV-luciferase and 
pTKGH were transfected to NIH/3T3 cells. 
Cotransfection of pcDSRcurasvan2 or addition of TPA 
or BtzcAMP to NIH/3T3 cells directed expression of c- 
fos-luciferase and pRSV-luciferase (Table II). Since the 
luciferase fusion genes contain the signal for a 
polyadenylation addition upstream from the 
enhancer/promoters, the background level of the ex- 
pression was very low compared with those of the CAT 
fusion genes 1161. The levels of the growth hormone 
derived from pTKGH were almost the same among the 
transfected cells in each experiment (data not shown). 
3.2. SRECAT and TRECAT expression by cotrans- 
fection of the c-Ha-rasw’12 cDNA 
The enhancer/promoter sequences of the CAT fu- 
sion genes described above contain the various 
Table I 
Activation of the CAT fusion genes by cotransfection of the c-Ha-r&“‘* cDNA to NIH/3T3 cells 
c-fosCAT pMTCAT pSV2CAT pRSVCAT Somatostatin-CAT 
None 
TPA (100 nM) 
BtzcAMP (2 mM) 
pcDSRa 
pcDSRarus 
pcD.SRcuru~“~‘~ 
1.5% (1.0) 
6.8% (4.5) 
4.3% (2.9) 
1.5% (1.0) 
2.1% (1.3) 
7.5% (5.0) 
2.4% (1 .O) 
5.0% (2.1) 
2.7% (1.1) 
2.3% (1.0) 
2.4% (1 .O) 
8.4% (3.5) 
2.0% (1.0) 
4.5% (2.3) 
4.4% (2.2) 
2.0010 (1 .O) 
2.5% (1.3) 
6.7010 (3.4) 
4.6% (1 .O) 
12.0% (2.6) 
10.6% (2.3) 
4.9% (1.1) 
6.1% (1.3) 
37.0% (8.0) 
0.7% ( 1.0) 
0.9% ( 1.3) 
7.2% (10.0) 
0.8% ( 1.1) 
0.7% ( 1.0) 
0.9% ( 1.3) 
pcDSRcu, pcDSRarus or pcDSRcYru@i* was cotransfected with c-fosCAT, pMTCAT, pSVZCAT, pRSVCAT or somatostatin-CAT and pTKGH 
to NlH/3T3 cells. TPA or BtzcAMP was added to the cells transfected with the CAT fusion genes and pTKGH 8 h before the harvest of the 
cells. CAT activity and the levels of growth hormone were then assayed as described under section 2. Each value represents the percentage of 
the conversion of chloramphenicol into the acetylated forms. The numbers in parentheses indicate the fold of induction. Essentially identical 
results were obtained in three independent experiments 
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Table II 
Activation of the luciferase fusion genes by cotransfection of the c- 
Ha-rasvau2 cDNA to NIH/3T3 cells 
c-fos-luciferase pRSV-luciferase 
(relative light units) 
None 2 2 
TPA (100 nM) 83 124 
Bt2cAMP (2 mM) 62 92 
pcDSRrv 2 2 
pcDSRarus 20 31 
p~DSRLuras’~*‘~ 134 422 
pcDSRa, pcDS.Rcuras or pcDS~rusvau2 was cotransfected with c- 
fos-luciferase or pRSV-luciferase and pTKGH to NIH/3T3 cells. 
TPA or Bt2cAMP was added to the cells transfected with the c-fos- 
luciferase or pRSV-luciferase and pTKGH 8 h before the harvest of 
the cells. Luciferase activity and the levels of growth hormone were 
then assayed as described under section 2. Essentially identical results 
were obtained in three independent experiments 
enhancer motifs such as the SRE, the CRE and/or the 
TRE [7-121. To determine which element is responsible 
for the rasva”’ p214nduced expression of the CAT fu- 
sion genes, the SRE, the CRE and the TRE were syn- 
thesized and inserted into AIL3CAT, which lacked the 
enhancer motif but contained the intact mouse in- 
terleukin 3 promoter region, to yield SRECAT, 
CRECAT and TRECAT, respectively [12]. AIL3CAT 
consists of the transcriptional initiation site and the 
CAT reporter gene [21]. Cotransfection of 
pcDSRcurasVan2 with SRECAT or TRECAT to 
NIH/3T3 cells increased CAT activity, whereas 
cotransfection with CRECAT did not increase CAT ac- 
tivity (Table III). Similar results were obtained when 
the cells transfected with these CAT fusion genes were 
stimulated by TPA. Bt2cAMP increased CAT activity 
in the cells transfected with CRECAT but not with 
SRECAT or TRECAT. Neither cotransfection of 
Table III 
Activation of SRECAT and TRECAT by cotransfection of the c-Ha- 
rasva’ 12 cDNA to NIH/3T3 cells 
SRECAT CRECAT TRECAT 
None 0.5% (1 .O) 0.6% (1.0) 1.1% (1.0) 
TPA (100 nM) 2.0% (4.0) 0.6% (1.0) 3.9% (3.5) 
BtzcAMP (2 mM) 0.6% (1.2) 4.6% (7.7) 1.3% (1.2) 
pcDSRa 0.5% (1.0) 0.7% (1.1) 1.2% (1.1) 
pcDSRcvras 0.8010 (1.6) 0.7% (1.1) 1.9% (1.7) 
pcDSRarusvBu2 2.9”/0 (5.8) 0.8% (1.3) 6.6% (6.0) 
pcDSRru, pcDSRcvras or pcDSRrYras’a”2 was cotransfected with 
SRECAT, CRECAT or TRECAT and pTKGH to NIH/3T3 cells. 
TPA or Bt2cAMP was added to the cells transfected with the CAT 
fusion genes and pTKGH 8 h before the harvest of the cells. CAT 
activity and the levels of growth hormone were then assayed as 
described under section 2. Each value represents the percentage of the 
conversion of chloramphenicol into the acetylated forms. The 
numbers in parentheses indicate the fold of induction. Essentially 
identical results were obtained in three independent experiments 
pcDSRarasvau2 nor the addition of TPA or BtzcAMP 
to the cells transfected with AIL3CAT increased CAT 
activity (data not shown). 
3.3. Effect of the down-regulation of protein kinase C 
on SRECA T, CRECA T and TRECA T expression 
In the last set of experiments, it was examined 
whether the rasvd12 p21-induced expression of the CAT 
fusion genes is mediated through protein kinase C. Pro- 
longed treatment of NIH/3T3 cells with PDBu caused 
the down-regulation of protein kinase C as described 
[12]. In these cells, TPA did not stimulate SRECAT or 
TRECAT expression, whereas transfection of 
pcDSRcurasva”’ induced expression of these CAT fu- 
sion genes in the control and PDBu-treated cells to a 
similar extent (Table IV). BtzcAMP also induced 
CRECAT expression in both the control and PDBu- 
treated cells (data not shown). 
Table IV 
Activation of SRECAT and TRECAT by cotransfection of the c-Ha-r&‘““2 cDNA to the PDBu-treated NlH/3T3 cells 
SRECAT TRECAT 
Control PDBu-treated Control PDBu-treated 
cells cells cells cells 
None 0.5% (1.0) 0.6% (1 .O) 1.0% (1.0) 0.9% (1 .O) 
TPA (100 nM) 2.1% (4.2) 0.6% (1.0) 3.7% (3.7) 0.9% (1 .O) 
pcDS~rasv*‘2 3.2% (6.4) 3.3% (5.5) 6.3% (6.3) 6.1% (6.8) 
pcDS&r&u2 was cotransfected with SRECAT or TRECAT and pTKGH to NIH/3T3 cells. The cells were incubated with 800 nM PDBu for 
40 h. After washing with phosphate-buffered saline, TPA was added to the cells transfected with the CAT fusion genes 8 h before the harvest 
of the cells. CAT activity was measured as described under section 2. Each value represents the percentage of the conversion of chloramphenicol 
into the acetylated forms. The numbers in parentheses indicate the fold of induction. Essentially identical results were obtained in three 
independent experiments 
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4. DISCUSSION 
We have first shown here that the activated ras p21 
stimulates the enhancer/promoters of the c-fos gene, 
the metallothionein II* gene, the SV40 virus genome 
and the RS virus genome, and the SRE and the TRE in 
NIH/3T3 cells. We have then shown here that TPA 
stimulates these enhancer/promoters and enhancer 
motifs, but that BtzcAMP stimulates the enhancer/pro- 
moters of the c-fos and the somatostatin genes, the 
SV40 virus genome and the RS virus genome, and the 
CRE in NIH/3T3 cells. Thus, the specificity of the ac- 
tivated rus p21 towards these enhancer/promoters and 
enhancer motifs is similar to that of TPA but different 
from that of BtzcAMP. It is likely from this result that 
the activated ras p21 and protein kinase C stimulate 
these enhancer/promoters and enhancer motifs in a 
manner independent of protein kinase A in NIH/3T3 
cells. We have also shown here that the activated ru,s 
p21 stimulates the SRE and the TRE even in the cells 
whose protein kinase C is down-regulated to the same 
extent as those induced in the control cells. In these 
protein kinase C-down-regulated cells, TPA does not 
activate these elements. These results suggest hat the 
activated ras p21 stimulates these enhancer motifs in a 
manner independent of protein kinase C in NIH/3T3 
cells. 
We have previously shown that the activated ras p21 
activates the c-fos gene enhancer/promoter and the 
SRE but not the CRE in a manner independent of pro- 
tein kinases A and C in PC12 cells [6]. PC12 cells are 
differentiated into neuron-like cells in response to NGF 
and BtzcAMP [22,23]. The activated ras p21 induces 
the differentiation of PC12 cells and the microinjection 
of an anti-ras p21 monoclonal antibody inhibits the 
NGF-induced differentiation of PC12 cells [24,25]. 
NGF activates the c-fos gene enhancer/promoter and 
the SRE but not the CRE in a manner independent of 
protein kinases A and C [6]. It is likely from these 
observations that ras p21 is involved in the NGF- 
induced differentiation of PC12 cells into neuron-like 
cells. The present results together with these earlier 
observations indicate that ras p21 induces expression of 
genes having at least the SRE and the TRE in a manner 
independent of protein kinases A and C in both pro- 
liferating and differentiating states of cells. 
It has been considered that ras p21 serves as a 
transducer for extracellular signals such as growth fac- 
tors [1,25-281. The extracellular signals for the activa- 
tion of T(IS p21 have not, however, been determined. In 
this regard, it has recently been shown that PDGF 
receptor phosphorylates GTPase activating protein for 
ras p21 @as GAP) and may be linked to the regulation 
of ras p21 activity in NIH/3T3 cells [28-301. PDGF is 
known to stimulate the c-fos gene enhancer/promoter 
and the SRE [31]. Thus, it could be speculated that 
PDGF induces gene expression through the activation 
of ras ~21. It has been also shown that expression of the 
activated ras p21 stimulates the phosphorylation of the 
c-raf protein and may consequently activate its protein 
kinase activity [32,33]. We have recently shown that 
transfection of the cDNA of the activated c-rafprotein 
stimulates the c-fos gene enhancer/promoter, the SRE 
and the TRE in NIH/3T3 cells [12]. A similar observa- 
tion has been made by Jamal and Ziff [34]. Therefore, 
it is tempting to speculate that rus p21 induces gene ex- 
pression through the activation of the c-raf protein in 
NIH/3T3 cells. Further studies are necessary to under- 
stand the modes of activation and action of rots p21 and 
its physiological role in the regulation of gene expres- 
sion for growth and differentiation control. 
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